10x Genomics, Inc.
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
None of our directors or officers adopted, modified orterminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended December 31, 2025, as such terms are defined under Item 408(a) of Regulation S-K, except as follows:
On November 26, 2025, Sarah Teichmann, amember of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 7,579 shares of the Company’s common stock, subject to certain conditions. The expiration date of the trading arrangement is February 25, 2027.
On November 29, 2025, Serge Saxonov, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 100,000 shares of the Company’s common stock plus up to the number of net shares Dr. Saxonov receives upon vesting in 114,237 restricted stock units scheduled to vest during the term of the arrangement, subject to certain conditions. The expiration date of the trading arrangement is February 26, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.